HeadSense
Noninvasive Multiparameter Brain Monitoring
Company Overview
Snapshot
Founded in April 2011, HeadSense operates with 11–50 employees. The company has secured funding across two rounds from three investors.
Business overview
HeadSense Medical develops noninvasive intracranial pressure (ICP) monitors designed to assist in the treatment of patients suffering from severe traumatic brain injury (TBI), stroke, and brain tumors. The core technology involves a disposable headset that emits an acoustic signal through the skull, which is then analyzed by a proprietary signal-processing algorithm to determine ICP levels. The device integrates with tablets or smartphones for data analysis and display, serving the Health Tech & Life Sciences sector, particularly in digital healthcare and medical devices for hospitals and healthcare providers.
Strategic signal
In July 2013, HeadSense garnered attention for its intracranial pressure monitoring earbuds, which were highlighted for their potential to offer a non-invasive alternative to traditional methods that often require drilling into the skull. This development signaled a significant advancement in patient care for conditions like TBI, stroke, and brain tumors, positioning HeadSense as an innovator in medical device technology focused on improving patient outcomes and reducing invasive procedures.
Log in to access full profile ›Company Intelligence Q&A
- What is HeadSense's primary focus?
- HeadSense Medical is dedicated to developing noninvasive intracranial pressure (ICP) monitors for patients with severe traumatic brain injury (TBI), stroke, and brain tumors.
- When was HeadSense founded?
- HeadSense was founded in April 2011.
- Which investors participated in HeadSense's July 2013 funding round?
- In July 2013, HeadSense received funding from investors including GE Ventures and Pontifax.
- What is the core technology behind HeadSense's ICP monitor?
- The HeadSense ICP monitor uses an acoustic signal transmitted through the skull, which is then analyzed by a proprietary signal-processing algorithm to determine ICP levels in mmHg.
- Did HeadSense receive any non-equity funding?
- In November 2013, HeadSense secured a grant from the Office of the Chief Scientist.